Navigation Links
Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008

Bruker Daltonics today is showcasing several new high performance mass spectrometry products and applications for proteomics at the 7th HUPO World Congress 2008:

AMSTERDAM, The Netherlands (Business Wire EON) August 17, 2008 -- maXis™ is the world's first high speed Ultra High Resolution TOF (UHR-TOF) mass spectrometer platform, and truly represents a revolution in tandem mass spectrometry. maXis offers exceptional proteomics performance with sub-ppm mass accuracy, mass resolution of 40,000 to 60,000 across a broad mass range, outstanding sensitivity and five orders of dynamic range - all at the high spectral rate of 20 Hz for MS and MS/MS that is essential for quantitative proteomics and to take full advantage of ultra-high performance liquid chromatography. ETD II is the next-generation electron transfer dissociation module for Bruker's HCTultra™ high capacity ion trap. It is based on a novel and compact nCI (negative chemical ionization) source with increased ETD/PTR reactant ion generation, resulting in rapid, confident characterization of PTMs such as phosphorylations or glycosylations at sub-fmol sensitivity. In combination with the major and fundamental ETD efficiency and sensitivity advantages of the spherical high capacity trap design, ETD II is designed to provide the most sensitive, fastest and most robust ETD fragmentation. Due to HCTultra's inherent m/z range of greater 3,000 and its superior mass resolution that can resolve 3+ and 4+ charge states of peptides on-the-fly at full analytical speed, ETD/PTR on the HCT-Ultra can even be used for up to 12 kDa proteins and beyond. MALDI-TDS™ Top-Down Sequencing (TDS) solution provides unparalleled levels of information from undigested proteins in pharmaceutical and biotechnology applications, including C- and N- terminal assignments even in the case of N-terminally blocked proteins. MALDI-TDS is available on Bruker's top-of-the line ultraflex™ III TOF/TOF system for the characterization of PEGylation sites and other protein modifications of vital importance in fields such as recombinant protein production, biologics drug development and quality control. MALDI-TDS has clearly proven its usefulness in the recent ABRF Protein Research Group (PRG) 2008 Study for the identification and differentiation of various truncated proteins of the same origin and provided 100% protein sequence coverage. Bruker's unique SmartBeam™ is the enabling technology for MALDI-TDS, complemented by next generation BioTools 3.2 top-down bioinformatics. The high sensitivity SmartBeam™ MALDI ion funnel source has now been coupled with the ultra-high mass resolution apex-ultra™ FTMS, representing a 'perfect match' for MALDI small molecule tissue imaging, including drugs and metabolites from animals dosed at therapeutic levels, e.g. at or below 5 mg/kg. With mass resolution greater than 900,000 (at 7 Tesla), the cluttered spectra produced in small molecule MALDI imaging of tissue samples are readily resolved, allowing for the first time MALDI-MS imaging of small molecules without the requirement to use MS/MS (SRM) for chemical background suppression. The high mass accuracy combined with Bruker's SmartFormula™ software automatically provides sum formula determination for detected molecules. This new imaging solution promises to advance areas such as drug development and delivery, clinical and pathology research, as well as other areas such as lipidomics. EASY-nLC™ is a Bruker-supported nanoscale LC system with 1D and 2D separation capabilities. Due to the true split-free gradient mixing it avoids cumbersome maintenance, and guarantees robust, steady and reliable operation. EASY-nLC dramatically reduces total solvent consumption and enables fast separations with peak widths less than 5 sec. The control by Bruker's Hystar™ software supports all proteomics applications on the maxis, micrOTOF-Q II, HCT ion trap, Flex MALDI and apex FTMS instrument series for complete, turn-key LC/MS/MS solutions. The new Bruker mass spectrometry products and applications for proteomics will be presented throughout the HUPO conference with more than 30 scientific contributions. During two Bruker Daltonics' luncheon seminars on Monday and Tuesday titled "(R)evolution in Biomarker Discovery", a prestigious researcher's panel including Helmut Meyer (MPC Bochum), Andrew Pitt (Univ. Glasgow) and Ron Heeren (FOM Amsterdam) will present talks detailing proteomics applications based on the novel developments.

Bruker Daltonics Executive Vice President Dr. Michael Schubert commented: "At this year's HUPO World Congress in Amsterdam, Bruker Daltonics is continuing its history of market leading innovations and is proudly releasing the maXis, an instrument with unprecedented, simultaneous high speed and ultra-high resolution performance across a broad mass range. In addition, Bruker Daltonics is greatly expanding the capabilities of its existing products through the release of several important enhancements, as well as new and innovative applications."

For further information on the HUPO conference, please see

For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit and

EASY-nLC(TM) is a trademark of Proxeon Biosystems, Denmark


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Zix Corporation Announces Webcast Showcasing Email Encryption Competitive Replacement
2. Better Nutrition Announces Best Of Beauty Awards Winners Showcasing the Best Natural Beauty Products of 2008
3. NIH scientists find a novel mechanism that controls the development of autoimmunity
4. Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
5. Novel Diagnostic Marker for Acute Kidney Injury Previewed at Abbott-Sponsored Scientific Workshop
6. Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
7. Finding suggests novel ways to boost vaccination or natural defenses
8. Novel hydrogel systems for dentin regeneration
9. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
10. Novel model of osteosarcoma
11. Novel DNA microarray chip predicts functional impairment and remission in rheumatoid arthritis
Post Your Comments:
Related Image:
 Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008 
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: